KoBioLabs, Inc.

As of June 30, 2026, KoBioLabs, Inc. carries a market capitalization of 62.63B, placing it among publicly traded companies globally. Its enterprise value stands at 47.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, KoBioLabs, Inc. has 19.42M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.83, and the price-to-book ratio stands at 2.18.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 47.93B versus a market cap of 62.63B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, KoBioLabs, Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.95, indicating elevated leverage, while an interest coverage ratio of -10.92 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, KoBioLabs, Inc. posted a negative return on equity (ROE) of -15.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.21, reflecting losses generated across the asset base. The company generates approximately 1.32B in revenue per employee across its workforce of 57.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.95 indicates how many times KoBioLabs, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, KoBioLabs, Inc. recorded 39.54M in income tax expense. The company reported a pretax loss of -4.75B and -4.80B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, KoBioLabs, Inc.'s stock has declined approximately 49.42% over the past 52 weeks. The 50-day moving average sits at 2,905.70, while the 200-day moving average is 4,243.70.

Over the twelve months ended June 30, 2026, KoBioLabs, Inc. generated 75.41B in revenue and converted that into -4.80B in net income, yielding earnings per share of -246.55. EBITDA reached -5.27B, while operating income came in at -8.07B.

As of June 30, 2026, KoBioLabs, Inc. holds 48.17B in cash and equivalents against 16.78B in total debt, resulting in a net debt position of 1.83B. Total book value stands at 28.73B, with working capital of 43.72B providing operational flexibility.

KoBioLabs, Inc. produced -2.45B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -551.28M in capital expenditures, free cash flow totaled -3.00B - equivalent to -154.43 per share.

Over the twelve months ended June 30, 2026, KoBioLabs, Inc. posted a gross margin of 74.95, reflecting its pricing power and cost economics. The operating margin of -10.70 and net profit margin of -6.37 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.29, meaning KoBioLabs, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, KoBioLabs, Inc. has an Altman Z-Score of -0.82, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.